CD137L、VEGF和E-cad在食管鳞癌组织中的表达及其与淋巴结转移、预后的相关性  

Expressions of CD137L,VEGF and E-cad in esophageal squamous cell carcinoma and their correlation with lymph node metastasis and prognosis

作　　者：胡锋超[1] 安秀英[1] 张晶 王萍[1] 窦艳[3] 张华英[3] HU Fengchao;AN Xiuying;ZHANG Jing;WANG Ping;DOU Yan;ZHANG Huaying(Department of Pathology,Hebei Civil Administration General Hospital,Xingtai Hebei 054000,China)

机构地区：[1]河北省民政总医院病理科,河北邢台054000 [2]河北省民政总医院肿瘤内科,河北邢台054000 [3]邢台市人民医院病理科,河北邢台054000

出　　处：《中国急救复苏与灾害医学杂志》2021年第8期902-906,共5页China Journal of Emergency Resuscitation and Disaster Medicine

基　　金：邢台市科技计划支撑项目(编号:2018zc127)。

摘　　要：目的探讨人CD137配体(CD137L)、血管内皮生长因子(vascular endothelial growth factor,VEGF)、E-钙黏蛋白(E-cadherin,E-cad)在食管鳞癌组织中的表达及与淋巴结转移、预后的相关性。方法免疫组化检测95例食管鳞癌组织和对应癌旁组织中CD137L、VEGF和E-cad表达,分析CD137L、VEGF和E-cad表达与临床病理特征的关系,随访患者生存情况,分析CD137L、VEGF和E-cad与生存预后的关系。结果CD137L和E-cad主要表达在细胞膜或少量细胞质,VEGF在食管癌组织中表达于胞质,食管癌组织CD137L和E-cad阳性率低于癌旁组织,VEGF表达阳性率高于癌旁组织,差异均有统计学意义(P<0.05)。TNM分期Ⅰ~Ⅱ期、肿瘤最大径<5 cm、浸润深度T1-T2食管癌患者CD137L阳性表达率显著高于TNM分期Ⅲ~Ⅳ期、肿瘤最大径≥5 cm、浸润深度T3-T4患者(P<0.05);TNM分期Ⅲ~Ⅳ期、有淋巴结转移、肿瘤最大径≥5 cm食管癌患者VEGF阳性表达率显著高于TNM分期Ⅰ~Ⅱ期、无淋巴结转移、肿瘤最大径<5 cm患者(P<0.05);TNM分期Ⅰ~Ⅱ期、无淋巴结转移、中高分化食管癌患者E-cad阳性表达率显著高于TNM分期Ⅲ~Ⅳ期、有淋巴结转移、低分化患者(P<0.05)。CD137L、E-cad阳性表达的食管癌患者生存期长于阴性表达患者(χ^(2)=17.980、7.197,均P<0.05);VEGF阳性表达的食管癌患者生存期短于阴性表达患者(χ^(2)=17.940,P<0.001)。COX回归分析发现,TNM分期、淋巴结转移、VEGF阳性表达是食管癌预后的危险因素,HR值分别为3.394、2.803、3.019,CD137L、E-cad阳性表达则是食管癌预后的保护因素。结论CD137L、VEGF和E-cad在食管鳞癌组织中存在差异表达,且与淋巴结转移和预后密切相关。Objective To investigate the expression of human CD137 ligand(CD137L),vascular endothelial growth fac⁃tor(VEGF),and E-cadherin(E-cad)in esophageal squamous cell carcinoma tissues and their correlation with lymph node metastasis and prognosis.Methods Immunohistochemistry was used to detect the expression of CD137L,VEGF and E-cad in 95 esophageal squamous cell carcinoma tissues and adjacent tissues.The relationship between the ex⁃pression of CD137L,VEGF and E-cad and clinicopathological characteristics was analyzed.Relationship between VEGF and E-cad and survival prognosis.Results CD137L and E-cad were mainly expressed in the cell membrane or a small amount of cytoplasm.VEGF was expressed in the cytoplasm in esophageal cancer tissues.The positive rates of CD137L and E-cad in esophageal cancer tissues were lower than those in the adjacent tissues.The differences were statistically significant(P<0.05).The positive rate of CD137L expression in patients with TNM stageⅠtoⅡ,tumor maximum diameter<5 cm,and depth of invasion T1-T2 esophageal cancer was significantly higher than that in pa⁃tients with TNM stage III to IV,tumor maximum diameter≥5 cm,and depth of invasion T3-T4(P<0.05);The positive expression rate of VEGF in patients with esophageal cancer with TNM stageⅢtoⅣ,with lymph node metastasis,and tumor maximum diameter≥5 cm was significantly higher than that in patients with TNM stageⅠtoⅡ,no lymph node metastasis,and tumor maximum diameter<5 cm(P<0.05)The positive expression rate of E-cad in patients with TNM stageⅠtoⅡ,no lymph node metastasis,and moderately and highly differentiated esophageal cancer was significantly higher than that in patients with TNM stageⅢtoⅣ,with lymph node metastasis,and poorly differentiated(P<0.05).CD137L,E-cad positive expression of esophageal cancer patients had longer survival than negative expression patients(χ^(2)=7.980,7.197,all P<0.05);VEGF positive expression of esophageal cancer patients had shorter survival time than negative expression patients(χ^

关 键 词：CD137L VEGF E-CAD 食管鳞癌 预后 

分 类 号：R735.1[医药卫生—肿瘤]